A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag180 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Oncologist, online erschienen am 11.05.2026. Verfasst von Julie N Graff und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA. Hauptthemen laut MEDLINE: Taxoids, Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Sanofi, Department of Defense Prostate Cancer Research.
Abstract (Originalsprache)
Background and Objective Despite treatment advances, treatment resistance for metastatic castration-resistant prostate cancer (mCRPC) is nearly universal. We studied the efficacy, safety, and pharmacokinetic properties of the combination of enzalutamide and cabazitaxel in patients with mCRPC. For phase 1, we examined the safety of combination therapy and determined the recommended phase 2 dose. Phase 2 primary endpoint included the percentage of patients achieving a ≥ 90% PSA decline (PSA90) as a measure of response to therapy.
Methods
A phase 1/2 single-arm, multi-institutional clinical trial enrolled adults with histologically confirmed progressive mCRPC without prior docetaxel or cabazitaxel chemotherapy for mCRPC. Co-administration of enzalutamide 160 mg orally once daily, cabazitaxel 25 mg/m2 IV once every 21 days, and prednisone 5 mg orally twice daily in mCRPC. Descriptive statistical analysis was used for all primary and secondary endpoints. Estimated proportions are with 95% confidence interval using the exact method. Key Findings The study met its primary endpoint with 61.1% (95% CI, 43.5% to 76.9%) of patients achieving PSA90. Observed toxicities were similar to those seen with either agent alone.
Conclusions
The combination of enzalutamide and cabazitaxel exhibited robust activity with tolerable side effects. Chemo-hormonal therapies warrant further study in mCRPC. What Does the Study Add This study of enzalutamide and cabazitaxel combination therapy in patients with advanced, pre-treated mCRPC showed promising efficacy, indicating strong rationale for further investigation. Patient Summary In this report we looked at outcomes for patients with metastatic prostate cancer treated at multiple institutions with enzalutamide and cabazitaxel at the same time after castration therapy alone had stopped working. We found the combination was safe and had anti-cancer effect, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Medical Oncology, School of Medicine, OHSU Knight Cancer Institute, Portland, OR, USA.
- Division of Hematology and Oncology, VA Portland Health Care System, Portland, OR, USA.
- Division of Hematology and Oncology, Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.
- Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- Department of Medicine (Division Hematology/Oncology), University of Washington School of Medicine, Seattle, WA, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
ORCID-Profile: Michael T Schweizer, Heather H Cheng
Förderung
- NCI NIH HHS
- Sanofi
- Department of Defense Prostate Cancer Research
- Astellas Pharma Global Development, Pfizer, Inc
- National Cancer Institute
Zitieren
APA
Graff, J. N., Smith, C. E. P., Sokolova, A. O., Qian, D. Z., Beer, T. M., Latour, E., Bailey, S., Kreitner, D., Grivas, P., Schweizer, M. T., Higano, C. S., Alumkal, J. J., Vuky, J., Yu, E. Y., & Cheng, H. H. (2026). A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag180
Vancouver
Graff JN, Smith CEP, Sokolova AO, Qian DZ, Beer TM, Latour E, et al. A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag180
BibTeX
@article{Graff2026,
author = {Graff, Julie N and Smith, Claire E P and Sokolova, Alexandra O and Qian, David Z and Beer, Tomasz M and Latour, Emile and Bailey, Shawna and Kreitner, Dustin and Grivas, Petros and Schweizer, Michael T and Higano, Celestia S and Alumkal, Joshi J and Vuky, Jacqueline and Yu, Evan Y and Cheng, Heather H},
title = {A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag180}
}
EUVIMED